Teva Cleared to Market Korlym Generic After Federal Circuit Upholds Ruling
Teva secured a Federal Circuit ruling affirming that its proposed Korlym generic does not infringe two of Corcept’s patents, removing a major legal barrier. This decision accelerates Teva’s pathway to market and could materially boost its generics segment upon regulatory approval.
1. Court Upholds No-Infringement Finding
The U.S. Court of Appeals for the Federal Circuit affirmed the New Jersey district court’s decision that Teva’s proposed generic version of Korlym does not infringe two of Corcept’s patents related to mifepristone dosing with strong CYP3A inhibitors.
2. Patent Shield Removed
With both patent challenges dismissed, Teva has cleared a significant legal hurdle, enabling the company to pursue approval and launch of its Korlym generic once remaining regulatory requirements are satisfied.
3. Financial and Competitive Impact
Entry of Teva’s generic is poised to erode a substantial portion of Corcept’s flagship franchise, potentially boosting Teva’s top-line in endocrine therapies and reinforcing its generics pipeline.